Compare VHI & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VHI | VIR |
|---|---|---|
| Founded | 1932 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 393.4M | 1.5B |
| IPO Year | 1994 | 2019 |
| Metric | VHI | VIR |
|---|---|---|
| Price | $14.17 | $8.38 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $12.00 | ★ $19.63 |
| AVG Volume (30 Days) | 14.4K | ★ 2.9M |
| Earning Date | 03-10-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,077,000,000.00 | $68,556,000.00 |
| Revenue This Year | $33.32 | N/A |
| Revenue Next Year | N/A | $1,049.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.44 | $4.16 |
| 52 Week High | $20.00 | $10.91 |
| Indicator | VHI | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 53.12 | 43.93 |
| Support Level | $12.24 | $5.14 |
| Resistance Level | $14.41 | $10.29 |
| Average True Range (ATR) | 0.70 | 0.47 |
| MACD | 0.09 | -0.19 |
| Stochastic Oscillator | 80.66 | 5.42 |
Valhi Inc is a holding company that provides chemicals, security products, waste management systems, and real estate development and management services through its subsidiaries. It operates its business in three segments, which are Chemicals, Component Products, and Real Estate Management and Development. The company derives maximum revenue from the Chemicals segment, which produces and markets value-added titanium dioxide pigments (TiO2). TiO2 is used to impart whiteness, brightness, opacity, and durability to various products, including paints, plastics, paper, fibers, and ceramics. Geographically, the company generates maximum revenue from the United States and also has a presence in Germany, Canada, Norway, and Belgium.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.